Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Fineline Cube May 13, 2026
Company Deals

Mindray Bio-Medical Re-Files for Hong Kong Listing After Initial Application Expiration

Fineline Cube May 12, 2026
Company Deals

Akari Therapeutics Partners with WuXi XDC to Advance Novel PH1 Payload Platform for Urothelial Cancer

Fineline Cube May 12, 2026
Company Deals

China Medical System Secures Exclusive China Rights to Pharmacosmos’ MonoFer and CosmoFer IV Iron Therapies

Fineline Cube May 12, 2026
Company Deals

Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization

Fineline Cube May 12, 2026
Policy / Regulatory

Hong Kong to Launch FDA-Style Medical Products Regulation Center by Year-End, Creating Gateway for Chinese Innovative Drugs

Fineline Cube May 13, 2026
Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Fineline Cube May 13, 2026
Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Fineline Cube May 13, 2026
Company Drug

Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub

Fineline Cube Oct 9, 2025

Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...

Company Drug

Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine

Fineline Cube Oct 9, 2025

China‑based Walvax Biotechnology Co., Ltd. (SHE: 300142) has secured market approval from the Jordan Food...

Company Drug

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

Fineline Cube Oct 9, 2025

China‑based Northeast Pharmaceutical Group Co., Ltd. (SHE: 000597) has announced that its chimeric antigen receptor...

Company Deals Drug

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Fineline Cube Oct 9, 2025

InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...

Company Drug

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Fineline Cube Oct 9, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration...

Company Drug

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors

Fineline Cube Oct 9, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the National Medical Products Administration...

Company Drug

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

Fineline Cube Sep 30, 2025

China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...

Company Deals

AstraZeneca Announces Dual‑Market Direct Listing on NYSE, Harmonising Global Share Structure

Fineline Cube Sep 30, 2025

AstraZeneca plc (AZ; NASDAQ: AZN) has unveiled a plan to standardise its share‑listing structure across...

Company Deals Drug

C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar

Fineline Cube Sep 30, 2025

C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...

Policy / Regulatory

NMPA Announces Import of Commercial‑Scale Pre‑Approval Overseas Drugs

Fineline Cube Sep 30, 2025

The National Medical Products Administration (NMPA) has issued a new regulatory framework, titled “Announcement on...

Company Deals

MicroPort Announces $680 Million Merger with CRM Cayman, Expanding Cardio‑Medical Footprint

Fineline Cube Sep 30, 2025

MicroPort Scientific Corporation (HKG: 0853) disclosed that CRM Cayman, MicroPort CardioFlow Medtech Corporation, and MicroPort CardioFlow...

Company Deals

Shanghai Junshi Biosciences Announces Nearly RMB 380 Million Capital Increase for Grit Biotechnology

Fineline Cube Sep 30, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) disclosed that its subsidiary, Shanghai JunTop...

Company Deals

AccurEdit Therapeutics Raises $75 M Series A, Secures Strategic Partners for Gene‑Editing Platform

Fineline Cube Sep 30, 2025

China‑based AccurEdit Therapeutics (Suzhou) Co., Ltd. announced that it has closed a US$75 million Series A financing...

Company Drug

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection

Fineline Cube Sep 30, 2025

China‑based Changchun GeneScience Pharmaceutical Co. Ltd. announced that its long‑acting recombinant human follicle‑stimulating hormone—CTP fusion...

Company Drug

Ipsen Launches BYLVAY in China for Rare Liver Disease

Fineline Cube Sep 30, 2025

France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...

Company Deals

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline

Fineline Cube Sep 30, 2025

China‑based TJ Biopharma announced today the successful completion of a Series C2 financing round that raised...

Company Deals

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

Fineline Cube Sep 30, 2025

Full‑Life Technologies, a global radiotherapeutics integrator, announced today the successful completion of $77 million in financing,...

Company

GSK Names Luke Miels as CEO to Drive Growth

Fineline Cube Sep 30, 2025

GlaxoSmithKline (GSK; NYSE: GSK) announced that Luke Miels has been appointed CEO Designate and will...

Company Drug

Simnova Secures FDA IND for CAR‑NK Therapy in SLE

Fineline Cube Sep 30, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova) announced that its CD19‑targeted chimeric antigen receptor gene‑modified natural...

Company Drug

Sinopharm Secures NMPA Approval for QuadrivalentHPV Vaccine

Fineline Cube Sep 29, 2025

China’s Sinopharm Group Co., Ltd. (Chengdu Institute of Biological Products, a subsidiary of the China...

Posts pagination

1 … 95 96 97 … 664

Recent updates

  • Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal
  • Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection
  • Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer
  • Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China
  • Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Boehringer Ingelheim Secures Global Rights to Immunitas’ First-in-Class Antibody Program for Chronic Inflammatory Diseases in €407.5M Deal

Company Medical Device

Roche Secures CE Mark for Elecsys pTau217 Blood Test, First Single-Assay Alzheimer’s Diagnostic with Amyloid Pathology Detection

Company Drug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

Company Drug

Bio-Thera’s CD25-Targeted ADC BAT8013 Receives NMPA Approval for Advanced Solid Tumor Clinical Studies in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.